Arix Bioscience plc notes positive clinical study announcements from Autolus Limited
September 18 2017 - 6:01AM
Arix Bioscience plc notes positive clinical
study announcements from Autolus Limited
LONDON, 18 September 2017: Arix
Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare
and life science company supporting medical innovation, is pleased
to note two positive press releases today by Autolus Limited
("Autolus"), an Arix Bioscience Group Business, announcing clinical
progress across its portfolio.
The first release today from Autolus announced
the completion of the first-dose cohort of its Phase I/II study of
AUTO2, its novel, dual-targeted Chimeric Antigen Receptor (CAR) in
patients with relapsed/refractory melanoma.
Autolus' AUTO2 is a CAR-T cell therapy that
targets both B-cell maturation antigen (BCMA) and transmembrane
activator and calcium modulator and cyclophilin ligand interactor
(TACI). AUTO2 re-programmes the patient's own T cells to minimize
the risk of cancer cells escaping treatment. AUTO2 is the first
example of Autolus' approach to unlocking the curative potential of
CAR-T cell therapies.
The second release today from Autolus announced
initiation of both the AMELIA and ALEXANDER Phase I/II studies for
AUTO3, its novel, dual-targeting, AUTO3 CAR T cell therapy, for
paediatric Acute Lymphocytic Leukaemia (ALL) and adult Diffuse
Large B-Cell Lymphoma (DLBCL).
Autolus' AUTO3 seeks to overcome two limitations
of current therapies by introducing dual targeting CARs and
addressing checkpoint mediated inhibition.
Joe Anderson, Chief Executive Officer of Arix
Bioscience, commented: "Cell therapy has the potential to
advance cancer treatment substantially and the announcements today
from Autolus are an important step in this campaign. CAR-T is
a proven, new approach to cancer treatment and Autolus has the
science and the team to substantially advance this field, with a
differentiated technology. We are privileged to work
with the company and our co-investors to help advance these
goals."
For more information, please contact:
Arix Bioscience plcJoe Anderson, CEO+44
(0) 20 7290 1052
Matthew Cole, Communications Director+44 (0) 20
7290 1065
Consilium Strategic
CommunicationsMary-Jane Elliott, Jessica Hodgson, Ivar
Milligan+44 (0)20 3709 5700arix@consilium-comms.com
About Arix Bioscience plcArix Bioscience
plc is a global healthcare and life science company supporting
medical innovation. Headquartered in London and with an
office in New York, Arix Bioscience sources, finances and
builds world class healthcare and life science businesses
addressing medical innovation at all stages of development.
Operations are supported by privileged access to breakthrough
academic science and strategic relationships with leading research
accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market
of the London Stock Exchange.
For further information, please
visit www.arixbioscience.com
About Autolus Limited
Autolus is a clinical-stage, biopharmaceutical
company, focused on the development and commercialisation of
engineered T-cell immunotherapy products to combat cancer.
Utilising its advanced cell programming and manufacturing
technologies, Autolus has a pipeline of products in development for
the treatment of both haematological malignancies and solid
tumours. For further information please visit the Company's
website at: www.autolus.com
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2024 to May 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2023 to May 2024